CAPRICOR THERAPEUTICS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 28, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

Bernstein Liebhard reminded Capricor Therapeutics investors of a September 28, 2026 deadline related to a securities-fraud class action filed against the company. The notice creates a legal overhang for NASDAQ: CAPR, though the release provides no allegations, damages estimate, or financial impact details.

Analysis

This is a low-information legal advertisement rather than a development that changes CAPR's clinical probability of success, cash runway, or commercial outlook. The near-term effect is nonetheless asymmetric because small-cap biotech holders are often momentum- and retail-heavy: renewed litigation visibility can widen bid-ask spreads and create forced selling into the September 28 lead-plaintiff deadline, particularly if short interest is elevated or financing is anticipated.

The relevant fundamental question is whether the alleged disclosure issue creates a credible risk of an FDA timing, manufacturing, safety, or efficacy revision. Absent a new regulatory filing, trial update, auditor issue, or company guidance change, the suit itself is unlikely to impair enterprise value; securities litigation is generally insured and economically immaterial relative to binary development risk. A meaningful downside repricing would require evidence that management withheld information that changes the probability-weighted value of CAPR's lead program.

Contrarian view: the headline may produce an investable liquidity dislocation, but only for investors who can independently underwrite the regulatory and cash-burn case. Litigation headlines frequently attract short interest after the underlying stock decline has already occurred; covering pressure can follow once the plaintiff deadline passes without a substantive new allegation. Do not treat that calendar event as a fundamental catalyst.

Over the next 1-3 months, monitor SEC filings, FDA correspondence disclosed by the company, trial/manufacturing updates, cash balance and any ATM usage. For the 6-18 month horizon, clinical and regulatory execution—not the class action—will determine whether CAPR warrants a durable valuation discount. Thesis is falsified on the bearish side by a clean regulatory/clinical update and no dilutive financing; it is confirmed by a guidance withdrawal, program delay, or capital raise at a material discount.

Key Decisions for Investors

• No directional position solely on this notice; classify CAPR as a litigation-driven liquidity watch through the September 28 deadline rather than a fundamental short catalyst.
• For existing CAPR longs, reduce tactical exposure or hedge into abnormal volume/volatility before September 28 unless the position is supported by a documented probability-weighted clinical thesis; reassess after the next SEC filing or corporate update.
• Consider a small, tightly risk-controlled short only if CAPR discloses a regulatory, manufacturing, or guidance deterioration and the stock fails to reprice; use a hard stop on a subsequent positive FDA/clinical update, where biotech gap risk can exceed 30-50%.
• Set alerts for ATM/prospectus supplements, quarterly cash runway disclosure, and FDA-related 8-Ks. A discounted equity raise would be the more actionable downside catalyst than progression of the securities case.